drug
Phenylketonuria (PKU)
Preclinicalupdated 6mo agoby Tessera Therapeutics Inc
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
News(4)
- Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell successBeam Therapeutics' risto-cel provided at least 12 consecutive months of freedom from severe pain crises for patients with sickle cell disease in a mid-stage trial, setting the stage for an FDA appl…biospace · 8d ago
- Plug-and-play gene therapy: FDA executes on vision that’s been in the works for yearsFormer biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” i…biospace · 17d ago
- Reusing data could cut R&D costs and greatly increase gene editing’s reach: ARMLeveraging recently proposed regulatory flexibilities, the gene-editing sector is working to cut R&D costs and unlock indications that were previously economically unviable, according to a new play…biospace · 1mo ago
- Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employeesSeven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in th…biospace · 3mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that